Sure, you’ve heard about Teva Pharmaceutical Industries’ (NYSE: TEVA) $40.5 billion acquisition of Allergan Generics (NYSE: AGN), announced on July 27. Less hyped was Teva Pharmaceuticals USA’s sale of 22 previously marketed generic drug brands to ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) for $25 million and a percentage of future gross profits from product sales. Earlier in the month, Indian drug maker Lupin Limited (NSE: LUPIN.NS) bought the Russian generic drug maker ZAO Biocom for an undisclosed price, and then U.S.-based generic formulator GAVIS Pharmaceuticals LLC and its manufacturing plant for $880 million. The day after the Teva/Allergan announcement, Hikma Pharmaceutical LLC agreed to pay $2.65 billion for Boehringer Ingelheim’s Roxane Laboratories, a specialty generic drug company in Ohio. It’s getting so you can’t tell the players without a program.
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
